keyword
MENU ▼
Read by QxMD icon Read
search

Menopausal hormonal therapy

keyword
https://www.readbyqxmd.com/read/28523945/prevention-of-postmenopausal-osteoporosis-in-chinese-women-a-5-year-double-blind-randomized-parallel-placebo-controlled-study
#1
S Y Ran, Q Yu, Y Chen, S Q Lin
OBJECTIVES: To observe the effectiveness and safety of menopause-related hormone therapy (MHT) to prevent bone loss in Chinese women during the menopausal transition and early menopause, as well as to evaluate the effects of 5-year MHT on overall health to add Level I evidence for the prevention of osteoporosis using MHT. DESIGN: This clinical study was a prospective, double-blind, randomized, parallel placebo-controlled study. Chinese women in the menopausal transition and early menopause were randomly allocated to the MHT group or the placebo group...
May 19, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28523253/cell-therapy-products-in-alzheimer-disease
#2
REVIEW
Hyeon Jin Song, Tae-Hee Kim, Hae-Hyeog Lee, Jun-Mo Kim, Yoo Jin Park, Arum Lee, Soo Ah Kim, Hye Ji Choi
We are rapidly becoming an aging society, with the ongoing increase in challenges of the elderly. The age-related cognitive decline in accordance with aging society is of major importance in public health. Recent studies have proved the impacts of sex-steroid hormone on the brain; compliant with aging, menopause and decrease in estrogen have an effect on the occurrence and prevention of Alzheimer's disease. A new hypothesis states that Alzheimer's disease is a postmenopausal dementia, and is a negative form of estrogen deficiency...
April 2017: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/28509627/impact-of-risk-reducing-salpingo-oophorectomy-in-premenopausal-women
#3
R F M Vermeulen, M van Beurden, C M Korse, G G Kenter
OBJECTIVES: To describe implications of premenopausal risk-reducing salpingo-oophorectomy (RRSO) on quality of life, endocrine symptoms, sexual function, osteoporosis, cardiovascular health, metabolic syndrome, cognitive impairment and safety of hormone replacement therapy. METHODS: We searched the following electronic databases: The Cochrane Library, EMBASE, PsycInfo, and MEDLINE. We selected controlled and uncontrolled trials of premenopausal women undergoing RRSO...
June 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28498913/the-management-of-menopause-in-women-with-a-history-of-endometriosis-a-systematic-review
#4
L C Gemmell, K E Webster, S Kirtley, K Vincent, K T Zondervan, C M Becker
BACKGROUND: Endometriosis is typically regarded as a premenopausal disease, resolving after natural or iatrogenic menopause due to declining oestrogen levels. Nonetheless, case reports over the years have highlighted the incidence of recurrent postmenopausal endometriosis. It is now clear that both recurrence and malignant transformation of endometriotic foci can occur in the postmenopausal period. Postmenopausal women are commonly treated with hormone replacement therapy (HRT) to treat climacteric symptoms and prevent bone loss; however, HRT may reactivate endometriosis and stimulate malignant transformation in women with a history of endometriosis...
May 11, 2017: Human Reproduction Update
https://www.readbyqxmd.com/read/28495834/testosterone-therapy-for-menopausal-women
#5
(no author information available yet)
It has been suggested that there is a link between low circulating concentrations of testosterone and reduced sexual functioning in postmenopausal women,(1) and it has been more than 60 years since the effects of testosterone therapy for the management of menopausal symptoms were first reported.(2) Since then, testosterone supplementation has received growing attention for its potential role in maintaining sexual function in menopausal women. The National Institute for Health and Care Excellence guideline on the diagnosis and management of menopause recommends considering testosterone supplementation for women with low sexual desire if hormone replacement therapy (HRT) alone has been ineffective...
May 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28492016/vaginal-rejuvenation-using-energy-based-devices
#6
REVIEW
Cheryl Karcher, Neil Sadick
Physiologic changes in a woman's life, such as childbirth, weight fluctuations, and hormonal changes due to aging and menopause, may alter the laxity of the vaginal canal, damage the pelvic floor, and devitalize the mucosal tone of the vaginal wall. These events often lead to the development of genitourinary conditions such as stress urinary incontinence; vaginal atrophy; dryness; and physiologic distress affecting a woman's quality of life, self-confidence, and sexuality. Various treatment modalities are currently available to manage these indications, varying from invasive vaginal surgery to more benign treatments like topical vaginal hormonal gels or hormone-replacement therapy...
September 2016: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/28487215/micturition-dysfunction-in-four-month-old-ovariectomized-rats-effects-of-testosterone-replacement
#7
Sandra M Bonilla-Becerra, Mariana G de Oliveira, Fabiano B Calmasini, Julio A Rojas-Moscoso, Angelina Zanesco, Edson Antunes
AIMS: Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats. MAIN METHODS: Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated...
May 6, 2017: Life Sciences
https://www.readbyqxmd.com/read/28486478/effect-of-chronic-estradiol-plus-progesterone-treatment-on-experimental-arterial-and-venous-thrombosis-in-mouse
#8
Marie-Cécile Valéra, Emmanuelle Noirrit-Esclassan, Marion Dupuis, Melissa Buscato, Alexia Vinel, Maeva Guillaume, Anne Briaux, Cédric Garcia, Thibaut Benoit, Olivier Lairez, Coralie Fontaine, Bernard Payrastre, Jean-François Arnal
Postmenopausal hormone replacement therapy (HRT) with estrogen plus progestogens is the first line therapy to treat menopausal symptoms. The progestogen is added to estrogen to reduce or eliminate the excess risk of endometrial cancer due to the unopposed effect of estrogen. Whereas progestin clearly opposes the proliferative and deleterious long-term actions of estrogen on the endometrium, the interference of progestin on the other estrogen action remains unclear. We previously reported that chronic subcutaneous 17α-estradiol (E2) in mice decreases platelet responsiveness, prolongs the tail-bleeding time and protects against acute thromboembolism...
2017: PloS One
https://www.readbyqxmd.com/read/28486246/menopause-and-postmenopausal-hormone-therapy-and-risk-of-hearing-loss
#9
Sharon G Curhan, A Heather Eliassen, Roland D Eavey, Molin Wang, Brian M Lin, Gary C Curhan
OBJECTIVE: Menopause may be a risk factor for hearing loss, and postmenopausal hormone therapy (HT) has been proposed to slow hearing decline; however, there are no large prospective studies. We prospectively examined the independent relations between menopause and postmenopausal HT and risk of self-reported hearing loss. METHODS: Prospective cohort study among 80,972 women in the Nurses' Health Study II, baseline age 27 to 44 years, followed from 1991 to 2013. Baseline and updated information was obtained from detailed validated biennial questionnaires...
May 8, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28486245/menopausal-hormone-therapy-and-national-time-trends-in-mortality-cautions-regarding-causal-inference
#10
JoAnn E Manson, Shari S Bassuk, C Noel Bairey Merz, Andrew M Kaunitz
No abstract text is available yet for this article.
May 8, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28476121/menopausal-hormone-therapy-a-systematic-review-of-cost-effectiveness-evaluations
#11
Louiza S Velentzis, Usha Salagame, Karen Canfell
BACKGROUND: Several evaluations of the cost-effectiveness (CE) of menopausal hormone therapy (MHT) have been reported. The aim of this study was to systematically and critically review economic evaluations of MHT since 2002, after the Women's Health Initiative (WHI) trial results on MHT were published. METHODS: The inclusion criteria for the review were: CE analyses of MHT versus no treatment, published from 2002-2016, in healthy women, which included both symptom relief outcomes and a range of longer term health outcomes (breast cancer, coronary heart disease, stroke, fractures and colorectal cancer)...
May 5, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28473671/prevalence-of-menopausal-symptoms-its-effect-to-quality-of-life-among-malaysian-women-and-their-treatment-seeking-behaviour
#12
B Abdullah, B Moize, B A Ismail, M Zamri, N F Mohd Nasir
INTRODUCTION: This study aimed to determine the prevalence of menopausal symptoms, its effect to the quality of life and their treatment seeking behaviour in a multiracial community in Malaysia. METHODS: This is a cross-sectional study involving postmenopausal women in Klang Valley, Malaysia. Data was obtained by face-to-face interview using standardised questionnaires on sociodemographic data, Menopause Rating Scale questionnaire, effect to quality of life and treatment sought...
April 2017: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28473194/association-of-catechol-o-methyltransferase-polymorphism-val158met-and-mammographic-density-a-meta-analysis
#13
Roope A Kallionpää, Elina Uusitalo, Juha Peltonen
OBJECTIVES: The Val158Met polymorphism in catechol-O-methyltransferase (COMT) enzyme reduces the methylation of catechol estrogens, which may affect mammographic density. High mammographic density is a known risk factor of breast cancer. Our aim was to perform meta-analysis of the effect of COMT Val158Met polymorphism on mammographic density. METHODS: Original studies reporting data on mammographic density, stratified by the presence of COMT Val158Met polymorphism, were identified and combined using genetic models Met/Val vs...
May 1, 2017: Gene
https://www.readbyqxmd.com/read/28471600/prolactin-and-estradiol-profile-in-a-cohort-of-colombian-women-with-systemic-lupus-erythematosus
#14
Carolina Aulestia, Alberto De Zubiría, Carlos Granados, Johanna Suárez, Ricard Cervera
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease with multiorgan involvement and wide variability in presentation and course. Although it can appear at any age, women of childbearing age are primarily affected. This has led to the proposal of a hormonal role in the development of SLE. Among the main hormones shown to have immunomodulatory effects are estradiol, progesterone and prolactin. OBJECTIVES: To report the levels of estradiol and prolactin in SLE patients and establish the relationship between these levels and disease activity, and to determine whether the phases of the menstrual cycle influence the activity of SLE and its relationship to hormone levels...
September 2016: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28457365/understanding-bone-damage-after-kidney-transplantation-a%C3%A2-retrospective-monocentric-cross-sectional-analysis
#15
M Gregorini, G Sileno, E F Pattonieri, V Corradetti, M Abelli, E Ticozzelli, L Scudeller, M A Grignano, P Esposito, L Bogliolo, A Giacomoni, T Rampino
BACKGROUND: Kidney transplantation (KT) immunosuppression may induce bone tissue damage with bone mineral density (BMD) loss increasing bone fractures risk. Steroid therapy is considered the major player, but others factors are still under review. PATIENTS AND METHODS: We designed an observational retrospective cohort study to evaluate bone damage after KT. The prevalence of osteopenia, osteoporosis, bone fractures, and the associated risk factors were investigated...
May 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28454109/anthropometric-clinical-and-molecular-determinants-of-treatment-outcomes-in-postmenopausal-hormone-receptor-positive-metastatic-breast-cancer-patients-treated-with-fulvestrant-results-from-a-real-word-setting
#16
Laura Pizzuti, Clara Natoli, Teresa Gamucci, Mariella Mauri, Domenico Sergi, Luigi Di Lauro, Giancarlo Paoletti, Enzo Ruggeri, Laura Iezzi, Isabella Sperduti, Lucia Mentuccia, Agnese Fabbri, Marcello Maugeri-Saccà, Luca Moscetti, Maddalena Barba, Patrizia Vici
To characterize determinants of treatment outcome in a real world population of 161 post-menopausal hormone receptor-positive metastatic breast cancer patients treated with fulvestrant. Descriptive statistics for demographics, anthropometrics, clinical and molecular characteristic were compared across subgroups of sensitivity/resistance to prior endocrine therapy and tested in uni/multivariate models. Clinical benefit was more common in sensitive patients with higher estrogen receptor expression and when fulvestrant was given in first line (p=0...
April 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28443200/epidemiology-of-ovarian-cancer-a-review
#17
Brett M Reid, Jennifer B Permuth, Thomas A Sellers
Ovarian cancer (OC) is the seventh most commonly diagnosed cancer among women in the world and the tenth most common in China. Epithelial OC is the most predominant pathologic subtype, with five major histotypes that differ in origination, pathogenesis, molecular alterations, risk factors, and prognosis. Genetic susceptibility is manifested by rare inherited mutations with high to moderate penetrance. Genome-wide association studies have additionally identified 29 common susceptibility alleles for OC, including 14 subtype-specific alleles...
February 2017: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28426980/hormonal-and-reproductive-risk-factors-of-papillary-thyroid-cancer-a-population-based-case-control-study-in-france
#18
Emilie Cordina-Duverger, Christophe Leux, Monica Neri, Catherine Tcheandjieu, Anne-Valérie Guizard, Claire Schvartz, Thérèse Truong, Pascal Guénel
The three times higher incidence of thyroid cancer in women compared to men points to a role of female sex hormones in its etiology. However the effects of these factors are poorly understood. We analyzed the association between thyroid cancer and hormonal and reproductive factors among women enrolled in CATHY, a population-based case-control study conducted in France. The study included 430 cases of papillary thyroid cancer and 505 controls frequency-matched on age and area of residence. The odds ratios for thyroid cancer increased with age at menarche (p trend 0...
April 17, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28426619/committee-opinion-no-698-hormone-therapy-in-primary-ovarian-insufficiency
#19
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28426614/committee-opinion-no-698-summary-hormone-therapy-in-primary-ovarian-insufficiency
#20
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
keyword
keyword
85110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"